Publications 2024

Bai B, Wise JF, Vodák D, Nakken S, Sharma A, Blaker YN, Brodtkorb M, Hilden V, Trøen G, Ren W, Lorenz S, Lawrence MS, Myklebost O, Kimby E, Pan-Hammarström Q, Steen CB, Meza-Zepeda LA, Beiske K, Smeland EB, Hovig E, Lingjærde OC, Holte H, Myklebust JH (2024)
Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma
14 (1), 147
DOI 10.1038/s41408-024-01124-5, PubMed 39191762

Sveen A, Johannessen B, Klokkerud SM, Kraggerud SM, Meza-Zepeda LA, Bjørnslett M, Bischof K, Myklebost O, Taskén K, Skotheim RI, Dørum A, Davidson B, Lothe RA (2024)
Evolutionary mode and timing of dissemination of high-grade serous carcinomas
9 (3)
DOI 10.1172/jci.insight.170423, PubMed 38175731

Publications 2023

Anzar I, Malone B, Samarakoon P, Vardaxis I, Simovski B, Fontenelle H, Meza-Zepeda LA, Stratford R, Keung EZ, Burgess M, Tawbi HA, Myklebost O, Clancy T (2023)
The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition
14, 1226445
DOI 10.3389/fimmu.2023.1226445, PubMed 37799721

Ballinger ML, Pattnaik S, Mundra PA, Zaheed M, Rath E, Priestley P, Baber J, Ray-Coquard I, Isambert N, Causeret S, van der Graaf WTA, Puri A, Duffaud F, Le Cesne A, Seddon B, Chandrasekar C, Schiffman JD, Brohl AS, James PA, Kurtz JE, Penel N, Myklebost O, Meza-Zepeda LA, Pickett H, Kansara M et al. (2023)
Heritable defects in telomere and mitotic function selectively predispose to sarcomas
379 (6629), 253-260
DOI 10.1126/science.abj4784, PubMed 36656928

Namløs HM, Khelik K, Nakken S, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA (2023)
Chromosomal instability and a deregulated cell cycle are intrinsic features of high-risk gastrointestinal stromal tumours with a metastatic potential
17 (11), 2432-2450
DOI 10.1002/1878-0261.13514, PubMed 37622176

Publications 2022

Fiorito E, Szybowska P, Haugsten EM, Kostas M, Øy GF, Wiedlocha A, Singh S, Nakken S, Mælandsmo GM, Fletcher JA, Meza-Zepeda LA, Wesche J (2022)
Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma
127 (11), 1939-1953
DOI 10.1038/s41416-022-01973-6, PubMed 36097178

Georgiesh T, Aggerholm-Pedersen N, Schöffski P, Zhang Y, Napolitano A, Bovée JVMG, Hjelle Å, Tang G, Spalek M, Nannini M, Swanson D, Baad-Hansen T, Sciot R, Hesla AC, Huang P, Dorleijn D, Haugland HK, Lacambra M, Skoczylas J, Pantaleo MA, Haas RL, Meza-Zepeda LA, Haller F, Czarnecka AM, Loong H et al. (2022)
Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour
127 (10), 1793-1798
DOI 10.1038/s41416-022-01959-4, PubMed 36030294

Giliberto M, Santana LM, Holien T, Misund K, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Coward E, Waage A, Taskén K, Skånland SS (2022)
Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines
12, 1040730
DOI 10.3389/fonc.2022.1040730, PubMed 36523963

Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
20 (1), 225
DOI 10.1186/s12967-022-03432-5, PubMed 35568909

Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
20 (1), 317
DOI 10.1186/s12967-022-03518-0, PubMed 35841045

Misund K, Hofste Op Bruinink D, Coward E, Hoogenboezem RM, Rustad EH, Sanders MA, Rye M, Sponaas AM, van der Holt B, Zweegman S, Hovig E, Meza-Zepeda LA, Sundan A, Myklebost O, Sonneveld P, Waage A (2022)
Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence
36 (7), 1887-1897
DOI 10.1038/s41375-022-01597-y, PubMed 35643867

Namløs HM, Skårn M, Ahmed D, Grad I, Andresen K, Kresse SH, Munthe E, Serra M, Scotlandi K, Llombart-Bosch A, Myklebost O, Lind GE, Meza-Zepeda LA (2022)
miR-486-5p expression is regulated by DNA methylation in osteosarcoma
23 (1), 142
DOI 10.1186/s12864-022-08346-6, PubMed 35172717

Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES, CONNECT Public–Private Partnership Consortium, Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R, InPreD-Norway and National Molecular Tumor Board Consortium, IMPRESS-Norway Consortium, Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å (2022)
A national precision cancer medicine implementation initiative for Norway
28 (5), 885-887
DOI 10.1038/s41591-022-01777-4, PubMed 35513529

Venizelos A, Engebrethsen C, Deng W, Geisler J, Geisler S, Iversen GT, Aas T, Aase HS, Seyedzadeh M, Steinskog ES, Myklebost O, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Lønning PE, Knappskog S, Eikesdal HP (2022)
Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
14 (1), 86
DOI 10.1186/s13073-022-01090-2, PubMed 35948919

Publications 2021

Bengtsen M, Winje IM, Eftestøl E, Landskron J, Sun C, Nygård K, Domanska D, Millay DP, Meza-Zepeda LA, Gundersen K (2021)
Comparing the epigenetic landscape in myonuclei purified with a PCM1 antibody from a fast/glycolytic and a slow/oxidative muscle
17 (11), e1009907
DOI 10.1371/journal.pgen.1009907, PubMed 34752468

Boye K, Longhi A, Guren T, Lorenz S, Næss S, Pierini M, Taksdal I, Lobmaier I, Cesari M, Paioli A, Løndalen AM, Setola E, Hompland I, Meza-Zepeda LA, Sundby Hall K, Palmerini E (2021)
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
70 (9), 2617-2624
DOI 10.1007/s00262-021-02876-w, PubMed 33580363

Georgiesh T, Namløs HM, Sharma N, Lorenz S, Myklebost O, Bjerkehagen B, Meza-Zepeda LA, Boye K (2021)
Clinical and molecular implications of NAB2-STAT6 fusion variants in solitary fibrous tumour
53 (6), 713-719
DOI 10.1016/j.pathol.2020.11.010, PubMed 33745702

Grad I, Hanes R, Ayuda-Durán P, Kuijjer ML, Enserink JM, Meza-Zepeda LA, Myklebost O (2021)
Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening
16 (3), e0248140
DOI 10.1371/journal.pone.0248140, PubMed 33690666

Hølmebakk T, Wiedswang AM, Meza-Zepeda LA, Hompland I, Lobmaier IVK, Berner JM, Stoldt S, Boye K (2021)
Integrating Anatomical, Molecular and Clinical Risk Factors in Gastrointestinal Stromal Tumor of the Stomach
28 (11), 6837-6845
DOI 10.1245/s10434-021-09605-8, PubMed 33651216

Reint G, Li Z, Labun K, Keskitalo S, Soppa I, Mamia K, Tolo E, Szymanska M, Meza-Zepeda LA, Lorenz S, Cieslar-Pobuda A, Hu X, Bordin DL, Staerk J, Valen E, Schmierer B, Varjosalo M, Taipale J, Haapaniemi E (2021)
Rapid genome editing by CRISPR-Cas9-POLD3 fusion
10
DOI 10.7554/eLife.75415, PubMed 34898428

Sveen A, Johannessen B, Eilertsen IA, Røsok BI, Gulla M, Eide PW, Bruun J, Kryeziu K, Meza-Zepeda LA, Myklebost O, Bjørnbeth BA, Skotheim RI, Nesbakken A, Lothe RA (2021)
The expressed mutational landscape of microsatellite stable colorectal cancers
13 (1), 142
DOI 10.1186/s13073-021-00955-2, PubMed 34470667

Publications 2020

Serguienko A, Braadland P, Meza-Zepeda LA, Bjerkehagen B, Myklebost O (2020)
Accurate 3-gene-signature for early diagnosis of liposarcoma progression
10, 4
DOI 10.1186/s13569-020-0126-1, PubMed 32158531

Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020)
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
4 (9), 1859-1866
DOI 10.1182/bloodadvances.2019001325, PubMed 32374878

Publications 2019

Forthun RB, Hovland R, Schuster C, Puntervoll H, Brodal HP, Namløs HM, Aasheim LB, Meza-Zepeda LA, Gjertsen BT, Knappskog S, Straume O (2019)
ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab
9 (1), 17471
DOI 10.1038/s41598-019-53917-5, PubMed 31767937

Goodridge JP, Jacobs B, Saetersmoen ML, Clement D, Hammer Q, Clancy T, Skarpen E, Brech A, Landskron J, Grimm C, Pfefferle A, Meza-Zepeda L, Lorenz S, Wiiger MT, Louch WE, Ask EH, Liu LL, Oei VYS, Kjällquist U, Linnarsson S, Patel S, Taskén K, Stenmark H, Malmberg KJ (2019)
Remodeling of secretory lysosomes during education tunes functional potential in NK cells
10 (1), 514
DOI 10.1038/s41467-019-08384-x, PubMed 30705279

Hanes R, Munthe E, Grad I, Han J, Karlsen I, McCormack E, Meza-Zepeda LA, Stratford EW, Myklebost O (2019)
Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
8 (2)
DOI 10.3390/cells8020189, PubMed 30795553

Namløs HM, Boye K, Meza-Zepeda LA (2019)
Cell-free DNA in blood as a noninvasive insight into the sarcoma genome
72, 100827
DOI 10.1016/j.mam.2019.10.004, PubMed 31703948

Pashov A, Shivarov V, Hadzhieva M, Kostov V, Ferdinandov D, Heintz KM, Pashova S, Todorova M, Vassilev T, Kieber-Emmons T, Meza-Zepeda LA, Hovig E (2019)
Diagnostic Profiling of the Human Public IgM Repertoire With Scalable Mimotope Libraries
10, 2796
DOI 10.3389/fimmu.2019.02796, PubMed 31849974

Publications 2018

Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, Meza-Zepeda LA, Hovig E, Myklebost O, Knappskog S, Lønning PE (2018)
Patterns of genomic evolution in advanced melanoma
9 (1), 2665
DOI 10.1038/s41467-018-05063-1, PubMed 29991680

Gouravan S, Meza-Zepeda LA, Myklebost O, Stratford EW, Munthe E (2018)
Preclinical Evaluation of Vemurafenib as Therapy for BRAF^V600E Mutated Sarcomas
19 (4)
DOI 10.3390/ijms19040969, PubMed 29570692

Kresse SH, Namløs HM, Lorenz S, Berner JM, Myklebost O, Bjerkehagen B, Meza-Zepeda LA (2018)
Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples
13 (5), e0197456
DOI 10.1371/journal.pone.0197456, PubMed 29771965

Løvf M, Zhao S, Axcrona U, Johannessen B, Bakken AC, Carm KT, Hoff AM, Myklebost O, Meza-Zepeda LA, Lie AK, Axcrona K, Lothe RA, Skotheim RI (2018)
Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity
75 (3), 498-505
DOI 10.1016/j.eururo.2018.08.009, PubMed 30181068

Namløs HM, Boye K, Mishkin SJ, Barøy T, Lorenz S, Bjerkehagen B, Stratford EW, Munthe E, Kudlow BA, Myklebost O, Meza-Zepeda LA (2018)
Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor
17 (11), 2473-2480
DOI 10.1158/1535-7163.MCT-18-0174, PubMed 30097488

Vodák D, Lorenz S, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O, Meza-Zepeda LA, Hovig E (2018)
Sample-Index Misassignment Impacts Tumour Exome Sequencing
8 (1), 5307
DOI 10.1038/s41598-018-23563-4, PubMed 29593270

Publications 2017

Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA (2017)
Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
16 (1), 116
DOI 10.1186/s12943-017-0691-y, PubMed 28683746

Chymkowitch P, P AN, Aanes H, Koehler CJ, Thiede B, Lorenz S, Meza-Zepeda LA, Klungland A, Enserink JM (2017)
Corrigendum: Sumoylation of Rap1 mediates the recruitment of TFIID to promote transcription of ribosomal protein genes
27 (2), 334
DOI 10.1101/gr.218370.116, PubMed 28148563

Engkvist ME, Stratford EW, Lorenz S, Meza-Zepeda LA, Myklebost O, Munthe E (2017)
Analysis of the miR-34 family functions in breast cancer reveals annotation error of miR-34b
Sci Rep, 7, 9655
DOI 10.1038/s41598-017-10189-1

Helland Å, Brustugun OT, Nakken S, Halvorsen AR, Dønnem T, Bremnes R, Busund LT, Sun J, Lorenz S, Solberg SK, Jørgensen LH, Vodak D, Myklebost O, Hovig E, Meza-Zepeda LA (2017)
High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival
141 (1), 184-190
DOI 10.1002/ijc.30726, PubMed 28387924

Namløs HM, Zaikova O, Bjerkehagen B, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA (2017)
Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report
17 (1), 29
DOI 10.1186/s12885-016-2992-8, PubMed 28061772

Rustad EH, Coward E, Skytoen ER, Misund K, Holien T, Standal T, Borset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A (2017)
Monitoring multiple myeloma by quantification of recurrent mutations in serum
Haematologica, 102 (7), 1266-1272
DOI 10.3324/haematol.2016.160564

Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA, Domingo E, Myklebost O, Kerr D, Tomlinson I, Nesbakken A, Skotheim RI, Lothe RA (2017)
Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1
9 (1), 46
DOI 10.1186/s13073-017-0434-0, PubMed 28539123

Publications 2016

Barøy T, Chilamakuri CS, Lorenz S, Sun J, Bruland ØS, Myklebost O, Meza-Zepeda LA (2016)
Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene
11 (9), e0163859
DOI 10.1371/journal.pone.0163859, PubMed 27685995

Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O, Børresen-Dale AL, Brustugun OT, Helland Å (2016)
TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
7, 85
DOI 10.3389/fgene.2016.00085, PubMed 27242894

Hanes R, Grad I, Lorenz S, Stratford EW, Munthe E, Reddy CC, Meza-Zepeda LA, Myklebost O (2016)
Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma
7 (34), 54583-54595
DOI 10.18632/oncotarget.10518, PubMed 27409346

Lorenz S, Barøy T, Sun J, Nome T, Vodák D, Bryne JC, Håkelien AM, Fernandez-Cuesta L, Möhlendick B, Rieder H, Szuhai K, Zaikova O, Ahlquist TC, Thomassen GO, Skotheim RI, Lothe RA, Tarpey PS, Campbell P, Flanagan A, Myklebost O, Meza-Zepeda LA (2016)
Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations
7 (5), 5273-88
DOI 10.18632/oncotarget.6567, PubMed 26672768

Våtsveen TK, Børset M, Dikic A, Tian E, Micci F, Lid AH, Meza-Zepeda LA, Coward E, Waage A, Sundan A, Kuehl WM, Holien T (2016)
VOLIN and KJON-Two novel hyperdiploid myeloma cell lines
55 (11), 890-901
DOI 10.1002/gcc.22388, PubMed 27311012

Publications 2015

Chymkowitch P, Nguéa AP, Aanes H, Koehler CJ, Thiede B, Lorenz S, Meza-Zepeda LA, Klungland A, Enserink JM (2015)
Sumoylation of Rap1 mediates the recruitment of TFIID to promote transcription of ribosomal protein genes
25 (6), 897-906
DOI 10.1101/gr.185793.114, PubMed 25800674

Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T, Dahmen I, Koker M, Schöttle J, Ullrich RT, Altmüller J, Becker C, Nürnberg P, Seidel H, Böhm D, Göke F, Ansén S, Russell PA, Wright GM, Wainer Z et al. (2015)
Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data
16 (1), 7
DOI 10.1186/s13059-014-0558-0, PubMed 25650807

Kanojia D, Nagata Y, Garg M, Lee DH, Sato A, Yoshida K, Sato Y, Sanada M, Mayakonda A, Bartenhagen C, Klein HU, Doan NB, Said JW, Mohith S, Gunasekar S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Myklebost O, Yang H, Dugas M, Meza-Zepeda LA, Silberman AW, Forscher C et al. (2015)
Genomic landscape of liposarcoma
6 (40), 42429-44
DOI 10.18632/oncotarget.6464, PubMed 26643872

Lilleby W, Vlatkovic L, Meza-Zepeda LA, Revheim ME, Hovig E (2015)
Translocational renal cell carcinoma (t(6;11)(p21;q12) with transcription factor EB (TFEB) amplification and an integrated precision approach: a case report
9, 281
DOI 10.1186/s13256-015-0749-7, PubMed 26654961

Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost O, Hovig E, Nakken S, Vodák D, Meza-Zepeda LA, Sandvik AK, Wader KF, Misund K, Sundan A, Aarset H, Waage A (2015)
BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis
5 (3), e299
DOI 10.1038/bcj.2015.24, PubMed 25794135

Serguienko A, Grad I, Wennerstrøm AB, Meza-Zepeda LA, Thiede B, Stratford EW, Myklebost O, Munthe E (2015)
Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA
6 (4), 2451-65
DOI 10.18632/oncotarget.3235, PubMed 25669981

Publications 2014

Barøy T, Kresse SH, Skårn M, Stabell M, Castro R, Lauvrak S, Llombart-Bosch A, Myklebost O, Meza-Zepeda LA (2014)
Reexpression of LSAMP inhibits tumor growth in a preclinical osteosarcoma model
13, 93
DOI 10.1186/1476-4598-13-93, PubMed 24885297

Chilamakuri CS, Lorenz S, Madoui MA, Vodák D, Sun J, Hovig E, Myklebost O, Meza-Zepeda LA (2014)
Performance comparison of four exome capture systems for deep sequencing
15 (1), 449
DOI 10.1186/1471-2164-15-449, PubMed 24912484

Garsed DW, Marshall OJ, Corbin VD, Hsu A, Di Stefano L, Schröder J, Li J, Feng ZP, Kim BW, Kowarsky M, Lansdell B, Brookwell R, Myklebost O, Meza-Zepeda L, Holloway AJ, Pedeutour F, Choo KH, Damore MA, Deans AJ, Papenfuss AT, Thomas DM (2014)
The architecture and evolution of cancer neochromosomes
26 (5), 653-67
DOI 10.1016/j.ccell.2014.09.010, PubMed 25517748

Håkelien AM, Bryne JC, Harstad KG, Lorenz S, Paulsen J, Sun J, Mikkelsen TS, Myklebost O, Meza-Zepeda LA (2014)
The regulatory landscape of osteogenic differentiation
32 (10), 2780-93
DOI 10.1002/stem.1759, PubMed 24898411

Skårn M, Noordhuis P, Wang MY, Veuger M, Kresse SH, Egeland EV, Micci F, Namløs HM, Håkelien AM, Olafsrud SM, Lorenz S, Haraldsen G, Kvalheim G, Meza-Zepeda LA, Myklebost O (2014)
Generation and characterization of an immortalized human mesenchymal stromal cell line
23 (19), 2377-89
DOI 10.1089/scd.2013.0599, PubMed 24857590

Publications 2013

Herlofsen SR, Bryne JC, Høiby T, Wang L, Issner R, Zhang X, Coyne MJ, Boyle P, Gu H, Meza-Zepeda LA, Collas P, Mikkelsen TS, Brinchmann JE (2013)
Genome-wide map of quantified epigenetic changes during in vitro chondrogenic differentiation of primary human mesenchymal stem cells
14, 105
DOI 10.1186/1471-2164-14-105, PubMed 23414147

Kuijjer ML, Peterse EFP, van den Akker BEWM, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O, Hassan AB, Hogendoorn PCW, Cleton-Jansen AM (2013)
IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma
BMC Cancer, 13, 245
DOI 10.1186/1471-2407-13-245

Lauvrak SU, Munthe E, Kresse SH, Stratford EW, Namløs HM, Meza-Zepeda LA, Myklebost O (2013)
Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes
109 (8), 2228-36
DOI 10.1038/bjc.2013.549, PubMed 24064976

Nome T, Thomassen GO, Bruun J, Ahlquist T, Bakken AC, Hoff AM, Rognum T, Nesbakken A, Lorenz S, Sun J, Barros-Silva JD, Lind GE, Myklebost O, Teixeira MR, Meza-Zepeda LA, Lothe RA, Skotheim RI (2013)
Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing
6 (5), 546-53
DOI 10.1593/tlo.13457, PubMed 24151535

Qu S, Olafsrud SM, Meza-Zepeda LA, Saatcioglu F (2013)
Rapid Gene Expression Changes in Peripheral Blood Lymphocytes upon Practice of a Comprehensive Yoga Program
PLoS One, 8 (4), e61910
DOI 10.1371/journal.pone.0061910

Schee K, Lorenz S, Worren MM, Günther CC, Holden M, Hovig E, Fodstad O, Meza-Zepeda LA, Flatmark K (2013)
Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer
8 (6), e66165
DOI 10.1371/journal.pone.0066165, PubMed 23824282

Publications 2012

Bjørnstad LG, Meza TJ, Otterlei M, Olafsrud SM, Meza-Zepeda LA, Falnes PØ (2012)
Human ALKBH4 interacts with proteins associated with transcription
7 (11), e49045
DOI 10.1371/journal.pone.0049045, PubMed 23145062

Chymkowitch P, Eldholm V, Lorenz S, Zimmermann C, Lindvall JM, Bjørås M, Meza-Zepeda LA, Enserink JM (2012)
Cdc28 kinase activity regulates the basal transcription machinery at a subset of genes
109 (26), 10450-5
DOI 10.1073/pnas.1200067109, PubMed 22689984

Kresse SH, Rydbeck H, Skårn M, Namløs HM, Barragan-Polania AH, Cleton-Jansen AM, Serra M, Liestøl K, Hogendoorn PC, Hovig E, Myklebost O, Meza-Zepeda LA (2012)
Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma
7 (11), e48262
DOI 10.1371/journal.pone.0048262, PubMed 23144859

Kuijjer ML, Rydbeck H, Kresse SH, Buddingh EP, Lid AB, Roelofs H, Burger H, Myklebost O, Hogendoorn PCW, Meza-Zepeda LA, Cleton-Jansen AM (2012)
Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data
Gene Chromosomes Cancer, 51 (7), 696-706
DOI 10.1002/gcc.21956

Namløs HM, Meza-Zepeda LA, Barøy T, Østensen IH, Kresse SH, Kuijjer ML, Serra M, Bürger H, Cleton-Jansen AM, Myklebost O (2012)
Modulation of the osteosarcoma expression phenotype by microRNAs
7 (10), e48086
DOI 10.1371/journal.pone.0048086, PubMed 23133552

Ohnstad HO, Castro R, Sun J, Heintz KM, Vassilev LT, Bjerkehagen B, Kresse SH, Meza-Zepeda LA, Myklebost O (2012)
Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma
119 (5), 1013-22
DOI 10.1002/cncr.27837, PubMed 23165797

Reikvam DH, Derrien M, Islam R, Erofeev A, Grcic V, Sandvik A, Gaustad P, Meza-Zepeda LA, Jahnsen FL, Smidt H, Johansen FE (2012)
Epithelial-microbial crosstalk in polymeric Ig receptor deficient mice
42 (11), 2959-70
DOI 10.1002/eji.201242543, PubMed 22865203

Skotheim RI, Meza-Zepeda LA, Hovig E, Lønning PE, Lothe RA, Myklebost O (2012)
[Genome sequencing for personalized cancer treatment]
132 (21), 2406-8
DOI 10.4045/tidsskr.12.0784, PubMed 23160594

Publications 2011

Dahlback HS, Brandal P, Krossnes BK, Fric R, Meling TR, Meza-Zepeda LA, Danielsen HE, Heim S (2011)
Multiple chromosomal monosomies are characteristic of giant cell ependymoma
42 (12), 2042-6
DOI 10.1016/j.humpath.2011.02.012, PubMed 21683982

Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad O, Smeland S, Hovig E (2011)
Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma
11, 455
DOI 10.1186/1471-2407-11-455, PubMed 22014070

Kresse SH, Meza-Zepeda LA, Machado I, Llombart-Bosch A, Myklebost O (2011)
Preclinical xenograft models of human sarcoma show nonrandom loss of aberrations
118 (2), 558-70
DOI 10.1002/cncr.26276, PubMed 21713766

Kuijjer ML, Namløs HM, Hauben EI, Machado I, Kresse SH, Serra M, Llombart-Bosch A, Hogendoorn PC, Meza-Zepeda LA, Myklebost O, Cleton-Jansen AM (2011)
mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts
4, 66
DOI 10.1186/1755-8794-4-66, PubMed 21933437

Reikvam DH, Erofeev A, Sandvik A, Grcic V, Jahnsen FL, Gaustad P, McCoy KD, Macpherson AJ, Meza-Zepeda LA, Johansen FE (2011)
Depletion of murine intestinal microbiota: effects on gut mucosa and epithelial gene expression
6 (3), e17996
DOI 10.1371/journal.pone.0017996, PubMed 21445311

Skårn M, Namløs HM, Noordhuis P, Wang MY, Meza-Zepeda LA, Myklebost O (2011)
Adipocyte differentiation of human bone marrow-derived stromal cells is modulated by microRNA-155, microRNA-221, and microRNA-222
21 (6), 873-83
DOI 10.1089/scd.2010.0503, PubMed 21756067

Publications 2010

Eide MB, Liestøl K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L, Myklebost O, Trøen G, Aamot HV, Holte H, Smeland EB, Delabie J (2010)
Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones
116 (9), 1489-97
DOI 10.1182/blood-2010-03-272278, PubMed 20505157

Henriksen J, Stabell M, Meza-Zepeda LA, Lauvrak SA, Kassem M, Myklebost O (2010)
Identification of target genes for wild type and truncated HMGA2 in mesenchymal stem-like cells
10, 329
DOI 10.1186/1471-2407-10-329, PubMed 20576167

Kresse SH, Ohnstad HO, Bjerkehagen B, Myklebost O, Meza-Zepeda LA (2010)
DNA copy number changes in human malignant fibrous histiocytomas by array comparative genomic hybridisation
5 (11), e15378
DOI 10.1371/journal.pone.0015378, PubMed 21085701

Kresse SH, Szuhai K, Barragan-Polania AH, Rydbeck H, Cleton-Jansen AM, Myklebost O, Meza-Zepeda LA (2010)
Evaluation of high-resolution microarray platforms for genomic profiling of bone tumours
3, 223
DOI 10.1186/1756-0500-3-223, PubMed 20691109

Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PCW, Buerger H, Aigner T, Gabbert HE, Poremba C (2010)
Molecular Characterization of Commonly Used Cell Lines for Bone Tumor Research: A Trans-European EuroBoNet Effort
Gene Chromosomes Cancer, 49 (1), 40-51
DOI 10.1002/gcc.20717

Publications 2009

Kresse SH, Ohnstad HO, Paulsen EB, Bjerkehagen B, Szuhai K, Serra M, Schaefer KL, Myklebost O, Meza-Zepeda LA (2009)
LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization
48 (8), 679-93
DOI 10.1002/gcc.20675, PubMed 19441093

Lehne G, Grasmo-Wendler UH, Berner JM, Meza-Zepeda LA, Adamsen BL, Flack A, Reiner A, Clausen OP, Hovig E, Myklebost O (2009)
Upregulation of stem cell genes in multidrug resistant K562 leukemia cells
33 (10), 1379-85
DOI 10.1016/j.leukres.2009.03.028, PubMed 19394083

Vatsveen TK, Tian E, Kresse SH, Meza-Zepeda LA, Gabrea A, Glebov O, Dai HY, Sundan A, Kuehl WM, Borset M (2009)
OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus
Leuk. Res., 33 (12), 1670-1677
DOI 10.1016/j.leukres.2009.03.001

Publications 2008

Kresse SH, Skårn M, Ohnstad HO, Namløs HM, Bjerkehagen B, Myklebost O, Meza-Zepeda LA (2008)
DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH
7, 48
DOI 10.1186/1476-4598-7-48, PubMed 18522746

Larsen E, Kleppa L, Meza TJ, Meza-Zepeda LA, Rada C, Castellanos CG, Lien GF, Nesse GJ, Neuberger MS, Laerdahl JK, William Doughty R, Klungland A (2008)
Early-onset lymphoma and extensive embryonic apoptosis in two domain-specific Fen1 mice mutants
68 (12), 4571-9
DOI 10.1158/0008-5472.CAN-08-0168, PubMed 18559501

Lybaek H, Meza-Zepeda LA, Kresse SH, Høysaeter T, Steen VM, Houge G (2008)
Array-CGH fine mapping of minor and cryptic HR-CGH detected genomic imbalances in 80 out of 590 patients with abnormal development
16 (11), 1318-28
DOI 10.1038/ejhg.2008.78, PubMed 18461090

Lyng H, Lando M, Brøvig RS, Svendsrud DH, Johansen M, Galteland E, Brustugun OT, Meza-Zepeda LA, Myklebost O, Kristensen GB, Hovig E, Stokke T (2008)
GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data
9 (5), R86
DOI 10.1186/gb-2008-9-5-r86, PubMed 18500990

Meza-Zepeda LA, Noer A, Dahl JA, Micci F, Myklebost O, Collas P (2008)
High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence
12 (2), 553-63
DOI 10.1111/j.1582-4934.2007.00146.x, PubMed 18419597

Roman E, Meza-Zepeda LA, Kresse SH, Myklebost O, Vasstrand EN, Ibrahim SO (2008)
Chromosomal aberrations in head and neck squamous cell carcinomas in Norwegian and Sudanese populations by array comparative genomic hybridization
20 (4), 825-43
PubMed 18813824

Roman E, Meza-Zepeda LA, Kresse SH, Myklebost O, Vasstrand EN, Ibrahim SO (2008)
Chromosomal aberrations in head and neck squamous cell carcinomas in Norwegian and Sudanese populations by array comparative genomic hybridization
Oncol. Rep., 20 (4), 825-843
DOI 10.3892/or_00000080

Publications 2007

Zangani MM, Frøyland M, Qiu GY, Meza-Zepeda LA, Kutok JL, Thompson KM, Munthe LA, Bogen B (2007)
Lymphomas can develop from B cells chronically helped by idiotype-specific T cells
204 (5), 1181-91
DOI 10.1084/jem.20061220, PubMed 17485509

Publications 2006

Meza-Zepeda LA, Kresse SH, Barragan-Polania AH, Bjerkehagen B, Ohnstad HO, Namløs HM, Wang J, Kristiansen BE, Myklebost O (2006)
Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas
66 (18), 8984-93
DOI 10.1158/0008-5472.CAN-06-1972, PubMed 16982739

Ree AH, Stokke T, Bratland A, Patzke S, Nome RV, Folkvord S, Meza-Zepeda LA, Flatmark K, Fodstad O, Andersson Y (2006)
DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting
26 (3A), 1909-16
PubMed 16827124

Ree AH, Stokke T, Bratland A, Patzke S, Nome RV, Folkvord S, Meza-Zepeda LA, Flatmark K, Fodstad O, Andersson Y (2006)
DNA damage responses in cell cycle G(2) phase and mitosis - Tracking and targeting
Anticancer Res., 26 (3A), 1909-1916

Sivertsen EA, Galteland E, Mu D, Holte H, Meza-Zepeda L, Myklebost O, Patzke S, Smeland EB, Stokke T (2006)
Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas
20 (3), 539-42
DOI 10.1038/sj.leu.2404094, PubMed 16437153

Publications 2005

Galteland E, Sivertsen EA, Svendsrud DH, Smedshammer L, Kresse SH, Meza-Zepeda LA, Myklebost O, Suo Z, Mu D, Deangelis PM, Stokke T (2005)
Translocation t(14;18) and gain of chromosome 18/BCL2: effects on BCL2 expression and apoptosis in B-cell non-Hodgkin's lymphomas
19 (12), 2313-23
DOI 10.1038/sj.leu.2403954, PubMed 16193090

Kresse SH, Berner JM, Meza-Zepeda LA, Gregory SG, Kuo WL, Gray JW, Forus A, Myklebost O (2005)
Mapping and characterization of the amplicon near APOA2 in 1q23 in human sarcomas by FISH and array CGH
4, 39
DOI 10.1186/1476-4598-4-39, PubMed 16274472

Publications 2004

Nilbert M, Meza-Zepeda LA, Francis P, Berner JM, Namløs HM, Fernebro J, Myklebost O (2004)
Lessons from genetic profiling in soft tissue sarcomas
75 (311), 35-50
DOI 10.1080/00016470410001708310, PubMed 15188664

Nilsson M, Meza-Zepeda LA, Mertens F, Forus A, Myklebost O, Mandahl N (2004)
Amplification of chromosome 1 sequences in lipomatous tumors and other sarcomas
109 (3), 363-9
DOI 10.1002/ijc.11716, PubMed 14961574

Wang J, Meza-Zepeda LA, Kresse SH, Myklebost O (2004)
M-CGH: analysing microarray-based CGH experiments
5, 74
DOI 10.1186/1471-2105-5-74, PubMed 15189572

Publications 2003

Meza-Zepeda LA (2003)
Molecular genetics of human sarcomas: a comprehensive study of two novel amplified regions in 1q21 and 12q14
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 89, 1 b. (flere pag.)
BIBSYS 030806151, ISBN 82-8072-066-9

Publications 2002

Meza-Zepeda LA, Forus A, Lygren B, Dahlberg AB, Godager LH, South AP, Marenholz I, Lioumi M, Flørenes VA, Maelandsmo GM, Serra M, Mischke D, Nizetic D, Ragoussis J, Tarkkanen M, Nesland JM, Knuutila S, Myklebost O (2002)
Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21
21 (14), 2261-9
DOI 10.1038/sj.onc.1205339, PubMed 11948409

Meza TJ, Stangeland B, Mercy IS, Skårn M, Nymoen DA, Berg A, Butenko MA, Håkelien AM, Haslekås C, Meza-Zepeda LA, Aalen RB (2002)
Analyses of single-copy Arabidopsis T-DNA-transformed lines show that the presence of vector backbone sequences, short inverted repeats and DNA methylation is not sufficient or necessary for the induction of transgene silencing
30 (20), 4556-66
DOI 10.1093/nar/gkf568, PubMed 12384603

Publications 2001

Forus A, Bjerkehagen B, Sirvent N, Meza-Zepeda LA, Coindre JM, Berner JM, Myklebost O, Pedeutour F (2001)
A well-differentiated liposarcoma with a new type of chromosome 12-derived markers
131 (1), 13-8
DOI 10.1016/s0165-4608(01)00516-7, PubMed 11734312

Forus A, D'Angelo A, Henriksen J, Merla G, Maelandsmo GM, Flørenes VA, Olivieri S, Bjerkehagen B, Meza-Zepeda LA, del Vecchio Blanco F, Müller C, Sanvito F, Kononen J, Nesland JM, Fodstad Ø, Reymond A, Kallioniemi OP, Arrigoni G, Ballabio A, Myklebost O, Zollo M (2001)
Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas-a possible mechanism for altering the nm23-H1 activity
20 (47), 6881-90
DOI 10.1038/sj.onc.1204874, PubMed 11687967

Forus A, Larramendy ML, Meza-Zepeda LA, Bjerkehagen B, Godager LH, Dahlberg AB, Saeter G, Knuutila S, Myklebost O (2001)
Dedifferentiation of a well-differentiated liposarcoma to a highly malignant metastatic osteosarcoma: amplification of 12q14 at all stages and gain of 1q22-q24 associated with metastases
125 (2), 100-11
DOI 10.1016/s0165-4608(00)00369-1, PubMed 11369052

Meza-Zepeda LA, Berner JM, Henriksen J, South AP, Pedeutour F, Dahlberg AB, Godager LH, Nizetic D, Forus A, Myklebost O (2001)
Ectopic sequences from truncated HMGIC in liposarcomas are derived from various amplified chromosomal regions
31 (3), 264-73
DOI 10.1002/gcc.1143, PubMed 11391797

Publications 1999

Ree AH, Tvermyr M, Engebraaten O, Rooman M, Røsok O, Hovig E, Meza-Zepeda LA, Bruland OS, Fodstad O (1999)
Expression of a novel factor in human breast cancer cells with metastatic potential
59 (18), 4675-80
PubMed 10493524